Niki Karachaliou Sign in to save

ORCID 0000-0002-2378-0498 OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (5)

3× The Healthcare Business of Merck KGaA, Darmstadt, Germany
1× Global Clinical Development, Merck, Darmstadt, Germany
1× Merck Healthcare KGaA, Darmstadt, Germany
1× Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany
1× Global Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany

Papers 7 stored

All · Aachen affiliation only

PCR18 CHANGES IN PAIN AND STIFFNESS EXPERIENCED BY PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) IN THE MANEUVER PHASE 3 TRIAL: INSIGHTS FROM EXIT INTERVIEWS
2026 Value in Health conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments

0

citations
Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.
2026 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments

0

citations
Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.
2026 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments

0

citations
Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.
2026 Journal of Clinical Oncology conference-abstract Medicine Musculoskeletal synovial abnormalities and treatments Open access

0

citations
PP01.28: Treatment Sequencing of Tepotinib in Patients With MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Outcomes From ≥3 Years Follow-Up of the VISION Study
2026 Journal of Thoracic Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations

0

citations
1995P Treatment (Tx) sequencing of tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Outcomes from ≥3 years follow-up of the VISION study
2025 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access

2

citations
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
2024 The Lancet Oncology article Medicine Lung Cancer Treatments and Mutations Open access

107

citations

7 results

Niki Karachaliou ▲ Sign in to save

Departments & institutes in Aachen

Papers 7 stored

Niki Karachaliou Sign in to save